Key result
NGAL and adiponectin levels were higher in LVAD recipients and heart failure patients compared to healthy controls, suggesting renal functions were not restored with circulatory support.
Why the study?
Renal dysfunction is a common complication in LVAD recipients linked to reduced survival, but conventional markers like serum creatinine and GFR have limitations.
Are levels of kidney biomarkers (NGAL, KIM-1, PAI-1, adiponectin) elevated in LVAD recipients compared to heart failure patients and healthy controls?
Observational (n=51)
Are levels of kidney biomarkers (NGAL, KIM-1, PAI-1, adiponectin) elevated in LVAD recipients compared to heart failure patients and healthy controls?
Kidney biomarkers NGAL and adiponectin remain elevated in LVAD recipients, suggesting renal function is not fully restored despite circulatory support.
Hypothesis-generating for persistent renal impairment despite LVAD; larger prospective studies needed before clinical adoption.
BACKGROUND/AIMS: Renal dysfunction or renal failure is a common complication in left ventricular assist device (LVAD) recipients and is associated with reduced survival. To date, serum creatinine and glomerular filtration rate (GFR) are used for the evaluation of kidney function. However, serum creatinine and GFR have limitations. The objective of our study is to assess the levels of kidney biomarkers in LVAD recipients compared to heart failure patients and healthy controls and to examine their association with conventional clinical biomarkers. METHODS: The biomarkers neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), plasminogen activator inhibitor-1 (PAI-1), and adiponectin were assessed in 51 participants: 19 heart failure patients, 16 LVAD recipients, and 16 healthy controls. Linear regressions were performed to assess whether demographic and clinical variables predict the levels of biomarkers that are associated with acute kidney injury and the risk of chronic kidney disease. RESULTS: The levels of NGAL and adiponectin were higher in LVAD recipients and patients with heart failure as compared with healthy controls. The levels of PAI-1 and KIM-1 were not elevated in LVAD recipients. The results of linear regression analysis indicated that when controlling for the effect of CRP and BNP, 40.1% of the variance in NGAL levels can be explained by GFR (R2 = 0.401, F = 5.56, p = 0.005), while CRP can explain 35.3% of the variance in adiponectin levels (R2 = 0.353, F = 4.55, p = 0.01), when controlling for the effect of BNP and GFR. CONCLUSIONS: The levels of NGAL and adiponectin were augmented in LVAD recipients, suggesting that renal functions were not restored with circulatory support. Larger studies should assess the predictability of these biomarkers of renal dysfunction in LVAD recipients.
No takes yet. Share an insight, caveat, or question.
Grosman‐Rimon et al. (2019) conducted an observational in Heart failure and left ventricular assist device (LVAD) implantation (n=51). LVAD implantation and heart failure vs. Healthy controls was evaluated on Levels of kidney biomarkers (NGAL, KIM-1, PAI-1, and adiponectin). NGAL and adiponectin levels were higher in LVAD recipients and heart failure patients compared to healthy controls, suggesting renal functions were not restored with circulatory support.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: